This revealed a statistically significant positive association between DNMT3A mutations and surface CD25 expression as well as a significant negative association in which patients with mutations in RUNX1 tended to have less CD33 on AML blasts (Fig. 2b). Here, RUNX1 is linked to acute myeloid leukemia.